

**Popis novih lijekova za koje je odobrenje dala Europska komisija od 1.02.2021. do 28.02.2021. godine/The list of new medicinal products authorised by the European Commission in February 2021**

<b>Redni broj/No.</b>	<b>Naziv lijeka/Name</b>	<b>Naziv djelatne tvari/Active Substance</b>	<b>Broj odobrenja EK / EC Authorisation number</b>	<b>ATK/ATC</b>
1.	Hepelisav B	hepatitis B surface antigen	EU/1/20/1503	J07BC01
2.	Inrebic *	fedratinib	EU/1/20/1514	L01XE57
3.	Kixelle	insulin aspart	EU/1/20/1506	A10AB05
4.	Lenalidomide Krka	lenalidomide	EU/1/20/1520	L04AX04
5.	Lenalidomide Krka d.d.	lenalidomide	EU/1/20/1521	L04AX04
6.	Lenalidomide Krka d.d. Novo mesto	lenalidomide	EU/1/20/1519	L04AX04
7.	Lumoxiti *	moxetumomab pasudotox	EU/1/20/1522	L01XC34
8.	Ogluo	glucagon	EU/1/20/1523	H04AA01
9.	Retsevmo	selpercatinib	EU/1/20/1527	L01EX22
10.	Rukobia	fostemsavir	EU/1/20/1518	J05AX29
11.	Sunitinib Accord	sunitinib	EU/1/20/1511	L01XE04
12.	Tukyza	tucatinib	EU/1/20/1526	L01EH03
13.	Yuflyma	adalimumab	EU/1/20/1513	L04AB04

\* lijek u EU ima "orphan" status/medicinal product with "orphan" designation